PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares

Posted by Brenda Bartman on Oct 7th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 1,638 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $64.03, for a total value of $104,881.14. Following the sale, the vice president owned 105,272 shares of the company’s stock, valued at approximately $6,740,566.16. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Elliott Boulding also recently made the following trade(s):

On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60.
On Monday, August 17th, Mark Boulding sold 2,813 shares of PTC Therapeutics stock. The shares were sold at an average price of $72.57, for a total transaction of $204,139.41.

PTC Therapeutics Trading Down 0.7%

PTC Therapeutics stock traded down $0.47 during trading on Wednesday, reaching $63.23. The company had a trading volume of 1,040,492 shares, compared to its average volume of 1,376,507. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of -109.02, a price-to-earnings-growth ratio of 1.96 and a beta of 0.49. The firm’s 50-day simple moving average is $68.92 and its 200 day simple moving average is $72.02. PTC Therapeutics, Inc. has a 52 week low of $61.23 and a 52 week high of $90.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.24 by $0.68. The company had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million. During the same period last year, the business earned ($0.83) EPS. The firm’s quarterly revenue was up 101.5% compared to the same quarter last year. On average, analysts predict that PTC Therapeutics, Inc. will post 1.17 earnings per share for the current year.

Institutional Trading of PTC Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new position in PTC Therapeutics during the 2nd quarter worth about $67,000. EverSource Wealth Advisors LLC raised its holdings in shares of PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 151 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of PTC Therapeutics in the 2nd quarter valued at about $81,000. Quantbot Technologies LP purchased a new stake in shares of PTC Therapeutics in the 2nd quarter worth approximately $112,000. Finally, GAMMA Investing LLC lifted its position in shares of PTC Therapeutics by 58.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 534 shares during the period.

Analyst Ratings Changes

PTCT has been the topic of several research analyst reports. Wall Street Zen raised shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 19th. Leerink Partners assumed coverage on shares of PTC Therapeutics in a report on Monday, September 14th. They issued an “outperform” rating and a $98.00 price target on the stock. Royal Bank Of Canada reissued a “sector perform” rating on shares of PTC Therapeutics in a report on Wednesday. Zacks Research lowered PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald raised their target price on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.08.

Read Our Latest Report on PTCT

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.